← Eichor
Condition: Neovascular Age Related Macular Degeneration Amd Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Neovascular Age Related Macular Degeneration Amd

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
Phase 1/Phase 2 · 1 location(s) · Shanghai Refreshgene Technology Co., Ltd. · NCT06141460A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD
Phase 2 · 1 location(s) · Innovent Biologics Technology Limited (Shanghai R&D Center) · NCT07275840Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting
Phase 4 · 1 location(s) · Medical University of Vienna · NCT05093374A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participant
Phase 3 · 36 location(s) · Amgen · NCT07614776Safety of BBC1501 Intravitreal Injection in Patients With Neovascular Age-Related Macular Degeneration (nAMD)
Phase 1 · 2 location(s) · Benobio Co., Ltd. · NCT05803785Gene Therapy(FT-003) for Wet AMD
Phase 1/Phase 2 · 1 location(s) · Frontera Therapeutics · NCT06492863Progression Suppression and Retinal Regression in VEGF-resistant AMD
NA · 1 location(s) · PharmaBio Corporation · NCT07005323Medico-economic Evaluation of Anti-VEGF Treatments in the Treatment of naïve Age-related Macular Degeneration (AMD): a M
Phase N/A · 1 location(s) · Centre Hospitalier Universitaire, Amiens · NCT03577041Extension Study for the Port Delivery System With Ranibizumab (Portal)
Phase 3 · 165 location(s) · Hoffmann-La Roche · NCT03683251Real-Life Clinical Outcomes of Aflibercept Biosimilar MY-1701P in the Treatment of Exudative Age-Related Macular Degener
Phase N/A · 1 location(s) · Saglik Bilimleri Universitesi · NCT07235527A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
Phase 2/Phase 3 · 91 location(s) · EyeBiotech Ltd. · NCT07440225Prognostic Role of Macular Neovascular Membrane Subtype in Pneumatic Displacement of Macular Hemorrhages
Phase N/A · 1 location(s) · Marco Mazzola · NCT07427160Ethical Issues of Using Gene Therapy in the Treatment of AMD
Phase N/A · 1 location(s) · Nantes University Hospital · NCT07004361Regulatory Post-Marketing Surveillance Study for Brolucizumab
Phase N/A · 28 location(s) · Novartis Pharmaceuticals · NCT04985487Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Relat
Phase 3 · 8 location(s) · Ocular Therapeutix, Inc. · NCT07516132Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)
Phase 3 · 31 location(s) · Innostellar Biotherapeutics Co.,Ltd · NCT07317934Identification of Molecular Signals in Vitreous Humor Associated With Suboptimal Response to Vascular Endothelial Growth
NA · 1 location(s) · Singapore National Eye Centre · NCT07249216Efficacy of Faricimab in Patients With Subretinal Hyper-reflective Material
Phase 4 · 10 location(s) · Biobizkaia Health Research Institute · NCT07403825Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Deg
Phase 3 · 79 location(s) · Adverum Biotechnologies, Inc. · NCT07482176CRISPR/cas13-medIated RNA TarGeting THerapy for the Treatment of Neovascular Age-related Macular Degeneration Investigat
EARLY_Phase 1 · 2 location(s) · HuidaGene Therapeutics Co., Ltd. · NCT06031727Real-World Evaluation of AI Enabled Multi-Spectral Imaging (MSI) for AMD Biomarker Detection
Phase N/A · 1 location(s) · AI-Spectral · NCT07446582A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Tre
Phase 4 · 52 location(s) · Genentech, Inc. · NCT04853251A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non
Phase 2 · 14 location(s) · Galimedix Therapeutics Inc · NCT06659549Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
Phase 3 · 181 location(s) · AbbVie · NCT05407636Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients With nAMD
Phase 1/Phase 2 · 1 location(s) · Sinocelltech Ltd. · NCT06672536Evaluate the Efficacy of Faricimab in Patients With Neovascular Age-related Macular Degeneration
Phase 4 · 5 location(s) · Junyeop Lee · NCT07367282Real-world Study of Aflibercept 8 mg in nAMD
Phase N/A · 27 location(s) · Peking University People's Hospital · NCT07640997Safety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients
EARLY_Phase 1 · 1 location(s) · Shanghai General Hospital, Shanghai Jiao Tong University Sch · NCT07053358Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macul
Phase 3 · 94 location(s) · 4D Molecular Therapeutics · NCT07064759A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO
Phase 2 · 49 location(s) · EyeBiotech Ltd. · NCT07205887
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.